Comparing two ways to give a new drug combo for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called AK104 given either as a shot under the skin or through an IV, combined with standard chemotherapy, for stomach or gastroesophageal junction cancer that has spread and hasn't been treated before. It aims to see which way of giving the drug works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer or cancer where the stomach meets the esophagus that has spread and cannot be removed with surgery.
- You have not received any prior chemotherapy or other systemic treatment for this cancer.
- You are well enough to be up and about (ECOG score 0 or 1).
- Your cancer can be measured on scans (RECIST 1.1).
- Your organs and bone marrow are working well enough to handle the treatment.
- You have not had treatment with immune checkpoint inhibitors before, and you haven't had bleeding, blood clots, or uncontrolled high blood pressure recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
This Phase 1/2 study tests the safety and effectiveness of two investigational drugs (AK109 and AK104) in people with advanced stomach (or lower esophagus/GEJ) cancer. It’s for cases where the cancer did not respond to first-line treatment that included anti–PD-1/PD-L1 therapy plus chemotherapy.
This trial is testing whether an experimental drug called AK112, combined with chemotherapy, can shrink stomach cancer before surgery, making it easier to remove. It is specifically for a type of stomach cancer that contains signet ring cells, and the goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.